Community oncologists play an important role in expanding access to clinical trials. Patel discusses the value of offering ...
Adding stereotactic body radiation therapy (SBRT) or surgery directed at every known metastasis to first-line systemic ...
Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.
However, the shift to precision oncology involves therapy based more on molecular profiles and the context of an individual ...
Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...
Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...
Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated ...
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...
However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...
Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...
Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results